“Evaluation of the topic use of natural compounds for the treatment of ocular surface inflammatory diseases”
Nikos Katsinas obtained his degree in Pharmacy (MPharm) in 2015 and his MScin Natural Product Chemistry (MSc Title: Isolation, Development, Production & Control of Bioactive Natural Products) in 2017 both by the Faculty of Pharmacy of the University of Athens (Greece).
During his Undergraduate studies, his Diploma thesis took place in Paris (University Paris-Descartes) within the framework of Erasmus program, regarding the purification of semi-synthetic molecules, gaining experience in the production of active molecules from semi-synthetic origin. His MSc thesis was part of the Marie-Curie E.U. funded program Microsmetics (FP7), accomplishing a bioguided chemical study of 2 microorganisms from the global biodiversity as a potent source of novel anti-ageing active ingredients. This work was carried out in collaboration with the Department of Cell Biology and Biophysics (Faculty of Biology) of the University of Athens in order to investigate the biological activity of the isolated molecules.
During his studies, he had also the chance to work in multinational companies like Korres Natural Products(placement during his MPharm) and Givaudan France SAS(placement during his MSc), but also later in Demo Pharmaceuticals SA. The opportunity to work for one year as a Formulation scientist in the R&D department of Demo, allowed him to study the pharmaceutical development of sterile formulations, while during his internship at the R&D department of Givaudan, his MSc research study was scaled-up into 30L bioreactors for industrial trials.
During the years, he also enjoyed the opportunity to transmit his knowledge on synthetic organic chemistry and cosmetic formulation by teaching theoretical courses of organic chemistry, control & evaluation of cosmetics and laboratory of cosmetic formulations at the Private Institute of Professional Training “AKMI”.
On October 2018, he initiated his PhD in the frame of the Marie – Curie E.U. funded program “Integrated Training in Dry Eye Disease Drug Development (IT-DED3)” (www.itded3.eu). The consortium of IT-DED³ is composed of 7 beneficiaries and 10 partners from 8 different European countries. In total, the project has 7 participating organizations from the non-academic sector, intending to go from R&D to proof of concept with a patient- and disease-driven mind set for the Dry Eye Disease. He was selected for the position ESR4 with title “Evaluation of the topic use of natural compounds for the treatment of ocular surface inflammatory diseases” at Institute of Applied Ophthalmobiology (IOBA) of the University of Valladolid in cooperation with the High Pressure Procedures Group (HPP).
He is fluent in English, French and Greek language, and … entry level in Spanish!